Documents | Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza | Guidance | NICE

Documents

A list of downloadable documents created during development.

Background information

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: review decision - November 2014 information
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: appendix A - GE decision paper - October 2014 ^{PDF 290.38 KB} 04 December 2014
Review Proposal - June 2014 information
Appendix A - provisional matrix of stakeholders ^{PDF 102.96 KB} 03 June 2014
Appendix B - addendum to the review considerations for TA158 and TA168 ^{PDF 146.11 KB} 03 June 2014
Appendix C - consultee and commentator comments on TA168 proposal ^{PDF 102.08 KB} 03 June 2014
Review decision - November 2011 information
Appendix A: decision paper presented to the Institute's Guidance Executive ^{PDF 78.64 KB} 28 November 2011
Review Proposal - September 2011 information
Appendix A: provisional matrix of stakeholders ^{PDF 68.45 KB} 06 October 2011
Appendix B: proposal paper presented to the Institute's Guidance Executive ^{PDF 280.31 KB} 06 October 2011

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: final appraisal determination

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: final appraisal determination information
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: final appraisal determination ^{PDF 126.13 KB} 08 August 2008
Response to consultee, commentator and public comments on the ACD and comments from website consultation ^{PDF 81.73 KB} 08 August 2008
Consultee and commentator comments on the ACD
Manufacturer/sponsor: GlaxoSmithKline ^{PDF 10.79 KB} 08 August 2008
Manufacturer/sponsor: Roche ^{PDF 89.13 KB} 08 August 2008
Professional and patient groups: British Thoracic Society ^{PDF 14.72 KB} 08 August 2008
Professional and patient groups: Diabetes UK ^{PDF 40.42 KB} 08 August 2008
Professional and patient groups: General Practice Airways Group ^{PDF 40.92 KB} 08 August 2008
Professional and patient groups: Health Protection Agency ^{PDF 22.81 KB} 08 August 2008
Professional and patient groups: Royal College of Paediatrics and Child Health ^{PDF 61.86 KB} 08 August 2008
Professional and patient groups: Royal College of Physicians ^{PDF 10.95 KB} 08 August 2008
Professional and patient groups: Royal College of Nursing ^{PDF 19.57 KB} 08 August 2008
Others: Department of Health ^{PDF 11.42 KB} 08 August 2008
Others: NHS Quality Improvement Scotland ^{PDF 19.8 KB} 08 August 2008
Others: Welsh Assembly Government ^{PDF 27.07 KB} 08 August 2008

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: appraisal consultation

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: appraisal consultation
Influenza (prophylaxis) - amantidine, oseltamivir and zanamivir: appraisal consultation document information
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: evaluation report
Evaluation report: overview ^{PDF 85.29 KB} 16 May 2008
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: assessment report ^{PDF 1.31 MB} 16 May 2008
Consultee and commentator comments on the assessment report
Consultee and commentator comments on the assessment report: British Thoracic Society ^{PDF 18.42 KB} 16 May 2008
Consultee and commentator comments on the assessment report: Diabetes UK ^{PDF 44.89 KB} 16 May 2008
Consultee and commentator comments on the assessment report: GlaxoSmithKline ^{PDF 27.21 KB} 16 May 2008
Consultee and commentator comments on the assessment report: Roche ^{PDF 97.5 KB} 16 May 2008
Consultee and commentator comments on the assessment report: Royal College of Nursing ^{PDF 13.05 KB} 16 May 2008
Consultee and commentator comments on the assessment report: Royal College of Physicians ^{PDF 13.53 KB} 16 May 2008
Non-manufacturer submissions
Non-manufacturer submissions: British Thoracic Society ^{PDF 54.58 KB} 16 May 2008
Non-manufacturer submissions: Diabetes UK ^{PDF 60.79 KB} 16 May 2008
Non-manufacturer submissions: Health Protection Agency ^{PDF 76.45 KB} 16 May 2008
Non-manufacturer submissions: Royal College of Nursing ^{PDF 13.98 KB} 16 May 2008
Non-manufacturer submissions: Royal College of Physicians ^{PDF 42.21 KB} 16 May 2008
Manufacturer submissions (executive summary only)
Manufacturer submissions (executive summary only): Roche ^{PDF 556.11 KB} 16 May 2008
Manufacturer submissions (executive summary only): GlaxoSmithKline ^{PDF 159.29 KB} 16 May 2008
Manufacturer submissions (executive summary only): Alliance Pharmaceuticals ^{PDF 14.45 KB} 16 May 2008
Expert written personal statements
Expert written personal statements: Fleming ^{PDF 140.55 KB} 16 May 2008
Expert written personal statements: Gunaratnam ^{PDF 30.64 KB} 16 May 2008
Expert written personal statements: Watson ^{PDF 25.79 KB} 16 May 2008

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: provisional matrix of consultees and commentators

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: provisional matrix of consultees and commentators ^{PDF 38.83 KB} 10 July 2007

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: draft scope

Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: draft scope ^{PDF 46.72 KB} 10 July 2007